Managing the lipid profile of coronary heart disease patients

References

• Martin SS, Abd TT, Jones SR, et al. 2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. J Am Coll Cardiol. 2014 Jun 24;63(24):2674–2678.
   Web of Science ®Google Scholar
• European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32(14):1769–1818.
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25Pt B):2889–2934.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S76–S99.
   Google Scholar
• Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25Pt B):2960–2984.
   PubMed Web of Science ®Google Scholar
• Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35(15):960–968.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Chapman MJ, de Backer G, et al. Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). Atherosclerosis. 2014;233(2):508–509.
   PubMed Web of Science ®Google Scholar
• Reiner Z. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus? Eur J Cardiovasc Prev Rehabil. 2011;18(5):724–727.
   PubMedGoogle Scholar
• Reiner Z. Similarities and differences between European and United States guidelines for the management of dyslipidaemias. Kardiol Pol. 2015;73(7):471–477.
   PubMed Web of Science ®Google Scholar
• Finkel JB, Duffy D. 2013 ACC/AHA cholesterol treatment guideline: paradigm shifts in managing atherosclerotic cardiovascular disease risk. Trends Cardiovasc Med. 2015;25(4):340–347.
   PubMed Web of Science ®Google Scholar
• Martin SS, Abd TT, Jones SR, et al. 2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. J Am Coll Cardiol. 2014;63(24):2674–2678.
   PubMed Web of Science ®Google Scholar
• Robinson JG. 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial? Curr Atheroscler Rep. 2014;16(6):413.
   PubMed Web of Science ®Google Scholar
• Smith SC Jr., Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol. 2014;64(6):601–612.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160(5):339–343.
   PubMed Web of Science ®Google Scholar
• Virani SS. What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults? Tex Heart Inst Journal. 2014;41(3):304–305.
   PubMed Web of Science ®Google Scholar
• Windler E, Zyriax BC. Cholesterol-lowering therapy: old evidence, new guidelines–which one to follow? A critical appraisal. Atheroscler Supplements. 2015;18:176–179.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315–2381.
   Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636–648.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart association task force on practice guidelines. Circulation. 2014;129(25Suppl 2):S76–99.
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1–113.
   PubMed Web of Science ®Google Scholar
• Asemi Z, Samimi M, Tabassi Z, et al. Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized clinical trial. Nutrition. 2014;30(11–12):1287–1293.
   PubMed Web of Science ®Google Scholar
• DASH Collaborative Research Group, Appel LJ, Moore TJ, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117–1124.
   PubMed Web of Science ®Google Scholar
• Siervo M, Lara J, Chowdhury S, et al. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr. 2015;113(1):1–15.
   PubMed Web of Science ®Google Scholar
• Zemel MB. Dietary pattern and hypertension: the DASH study. Dietary approaches to stop hypertension. Nutr Rev. 1997;55(8):303–305.
   PubMed Web of Science ®Google Scholar
• Lau KK, Wong YK, Chan YH, et al. Mediterranean-style diet is associated with reduced blood pressure variability and subsequent stroke risk in patients with coronary artery disease. Am J Hypertens. 2015;28(4):501–507.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Gheewala NM, O’Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol. 2008;51(3):249–255.
   PubMed Web of Science ®Google Scholar
• Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124(7):789–795.
   PubMed Web of Science ®Google Scholar
• Vanhees L, Geladas N, Hansen D, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol. 2012;19(5):1005–1033.
   PubMed Web of Science ®Google Scholar
• Vanhees L, Rauch B, Piepoli M, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular disease (Part III). Eur J Prev Cardiol. 2012;19(6):1333–1356.
   PubMed Web of Science ®Google Scholar
• Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–229.
   PubMed Web of Science ®Google Scholar
• Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116(19):2110–2118.
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Erlinger TP, Young DR, et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension. 2002;40(5):612–618.
   PubMed Web of Science ®Google Scholar
• Kelley GA, Kelley KS. Aerobic exercise and HDL2-C: a meta-analysis of randomized controlled trials. Atherosclerosis. 2006;184(1):207–215.
   PubMed Web of Science ®Google Scholar
• Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167(10):999–1008.
   PubMed Web of Science ®Google Scholar
• Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med. 2009;48(1):9–19.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682–692.
   PubMed Web of Science ®Google Scholar
• Prugger C, Wellmann J, Heidrich J, et al. Readiness for smoking cessation in coronary heart disease patients across Europe: results from the EUROASPIRE III survey. Eur J Prev Cardiol. 2015;22(9):1212–1219.
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121–137.
   PubMedGoogle Scholar
• Chu P, Pandya A, Salomon JA, et al. Comparative effectiveness of personalized lifestyle management strategies for cardiovascular disease risk reduction. J Am Heart Assoc. 2016;5(3):e002737.
   Google Scholar
• Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013 May 31;(5):CD009329.
   Google Scholar
• Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3–46.
   PubMed Web of Science ®Google Scholar
• Auer J, Weber T, Eber B. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;351(7):714–717. author reply −7.
   PubMedGoogle Scholar
• Dohi T, Miyauchi K, Okazaki S, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis. 2010 Jun;210(2):497–502.
   Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504.
   PubMed Web of Science ®Google Scholar
• Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358–2362.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
   PubMed Web of Science ®Google Scholar
• Trompet S, Postmus I, Slagboom PE, et al. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. Eur J Clin Pharmacol. 2016;72(4):431–437.
   PubMed Web of Science ®Google Scholar
• Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Freedman JE. Antioxidant versus lipid-altering therapy–some answers, more questions. N Engl J Med. 2001;345(22):1636–1637.
   PubMed Web of Science ®Google Scholar
• Michos ED, Sibley CT, Baer JT, et al. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (atherothrombosis intervention in metabolic syndrome with low HDL/High triglycerides: impact on global health outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol. 2012;59(23):2058–2064.
   PubMed Web of Science ®Google Scholar
• Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015;37(10):2153–2179.
   PubMed Web of Science ®Google Scholar
• SoRelle R. Niacin-simvastatin combination benefits patients with coronary artery disease. Circulation. 2001;104(24):E9050–60.
   Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–1592.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Chapman J, Wiklund O, et al. The new joint EAS/ESC guidelines for the management of dyslipidaemias. Atherosclerosis. 2011;217(1):1.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Farnier M, Foody JM, et al. Combination therapy in dyslipidemia: where are we now? Atherosclerosis. 2014;237(1):319–335.
   PubMed Web of Science ®Google Scholar
• Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• Group HTC, Mj L, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• Banach M, Nikolic D, Rizzo M, et al. IMPROVE-IT: what have we learned? Curr Opin Cardiol. 2016;31(4):426–433.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Bakker-Arkema RG, Best J, Fayyad R, et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis. 1997;131(1):17–23.
   PubMed Web of Science ®Google Scholar
• Choi HD, Shin WG, Lee JY, et al. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis. Vascul Pharmacol. 2015;65–66:23–30.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Gong RR, Qiu L, et al. Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2014;34(9):599–608.
   PubMed Web of Science ®Google Scholar
• Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia–Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006;7:35.
   PubMed Web of Science ®Google Scholar
• Da Silva PM. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs. 2011;11(2):93–107.
   PubMed Web of Science ®Google Scholar
• Achimastos A, Alexandrides T, Alexopoulos D, et al. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones. 2016;15(1):8–14.
   PubMedGoogle Scholar
• Ajufo E, Rader DJ. Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes Endocrinol. 2016;4(5):436–446.
   PubMed Web of Science ®Google Scholar
• Auer J, Berent R, Primus C. PCSK9 inhibitors and cardiovascular events. N Engl J Med. 2015;373(8):773.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Obradovic M, et al. PCSK9 inhibition - a novel mechanism to treat lipid disorders? Curr Pharm Des. 2013;19(21):3869–3877.
   PubMed Web of Science ®Google Scholar
• Yang E. PCSK9 inhibitors: are we on the verge of a breakthrough? Clin Pharmacol Ther. 2015;98(6):590–601.
   PubMed Web of Science ®Google Scholar
• Reiner Z. PCSK9 inhibitors–past, present and future. Expert Opin Drug Metab Toxicol. 2015;11(10):1517–1521.
   PubMed Web of Science ®Google Scholar
• Sible AM, Nawarskas JJ, Anderson JR. PCSK9 inhibitors: an innovative approach to treating hyperlipidemia. Cardiol Rev. 2016;24(3):141–152.
   PubMed Web of Science ®Google Scholar
• Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors–the clinical benefit of lipid drugs. N Engl J Med. 2015;373(17):1588–1591.
   PubMed Web of Science ®Google Scholar
• Farnier M. PCSK9: from discovery to therapeutic applications. Arch Cardiovasc Dis. 2014;107(1):58–66.
   PubMed Web of Science ®Google Scholar
• Drakopoulou M, Toutouzas K, Stefanadis C. Novel pharmacotherapies of familial hyperlipidemia. Pharmacol Ther. 2013;139(3):301–312.
   PubMed Web of Science ®Google Scholar
• Bergeron N, Ba P, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–1666.
   PubMed Web of Science ®Google Scholar
• Della Badia LA, Elshourbagy NA, Mousa SA. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Pharmacol Ther. 2016;164:183–194.
   PubMed Web of Science ®Google Scholar
• White CM. Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab. Ann Pharmacother. 2015;49(12):1327–1335.
   PubMed Web of Science ®Google Scholar
• Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). Plos One. 2013;8(5):e64145.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115(9):1212–1221.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–689.
   PubMed Web of Science ®Google Scholar
• Cho L, Rocco M, Colquhoun D, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014;37(3):131–139.
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–2548.
   PubMed Web of Science ®Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497–2506.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-Controlled DESCARTES study. Circ Res. 2015;117(8):731–741.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opin Drug Saf. 2014;13(8):1023–1030.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Tartagni E, Ertek S. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. Expert Opin Biol Ther. 2014;14(6):863–868.
   PubMed Web of Science ®Google Scholar
• Smith L, Mosley J, Yates J, et al. The new face of hyperlipidemia management: proprotein Convertase Subtilisin/Kexin inhibitors (PCSK-9) and their emergent role as an alternative to statin therapy. J Pharm Pharm Sci. 2016;19(1):137–146.
   PubMed Web of Science ®Google Scholar